A. Graham Pockley, Phd Email & Phone Number

Munich Area, Germany

multimmune GmbH is a private, clinical-stage biopharmaceutical company which has developed a unique and proprietary technology platform on the basis of the founding scientists' (Professor Gabriele Multhoff, Dr Claus Botzler) discovery that cell surface-bound Hsp70 is uniquely expressed on a large proportion of cancers (~50-75%), but not on healthy cells. This makes this form of Hsp70 an excellent and broadly-applicable molecule on which to base the development of innovative therapeutics and diagnostics ('theranostics').A Phase I clinical trial of our first generation, non-expanded TKD/IL-2 activated autologous NK cell therapy (ENKASTIM™) involving eleven (11) patients with metastatic colorectal cancer and one (1) patient with non-small lung cancer (NSCLC) after standard of care (SOC) in Germany demonstrated safety and signs of efficacy. A Phase IIa (randomized, controlled) clinical trial of ENKASTIM™ involving fourteen (14) patients with advanced (Stage IIIb) NSCLC conducted in Germany demonstrated promising clinical benefit and survival.Alphageneron Pharmaceuticals Inc. USA and multimmune GmbH, Germany signed an Exclusive Worldwide License, and an Option to Purchase Agreement for its immunotherapy and diagnostics platform technology, in 2020.An Investigator-Initiated IND for a Phase I/IIa Clinical Open Label Combination Trial with our licensees' (Alphageneron Pharmaceuticals Inc.) next generation expanded, TKD/IL-2 activated autologous NK cell drug product (AP-144™) in combination with KEYTRUDA (pembrolizumab) in patients with metastatic (Stage IV) NSCLC in the United States is currently under consideration by the FDA.

Boston, Massachusetts, United States

Radiance Biopharma, Inc. (“Radiance”) is a privately-held immunooncology focussed biotechnology company developing next generation Antibody Drug Conjugates (ADCs). ADCs comprises a monoclonal antibody or monoclonal antibodies that are directed towards target antigens expressed on the cancer cell surface conjugated to a cytotoxic payload via a chemical linker. This approach reduces systemic exposure to toxic drugs and and therefore toxicity and harmful side-effects. Radiance is developing novel ADCs that have a better safety profile by reducing the incidence of off-target side effects.Our lead product candidates are RB-201™, a bispecific ADC targeting tumors co-expressing HER-2 and TROP-2 and RB-203™, an ADC targeting tumors expressing an undisclosed target (‘XXX’).

Boston, Massachusetts, United States

We are a pioneering biotechnology company specializing in liquid biopsy-based cancer diagnostic tests. With headquarters in Cambridge, Massachusetts, USA and facilities in Munich, Germany, we are committed to developing and commercializing innovative liquid biopsy-based tests for cancer detection/diagnosis and disease monitoring.The concept of measuring exosomal Hsp70 as a cancer-specific biomarker and its diagnostic potential developed by multimmune GmbH has been studied in 448 patients covering a range of different cancer settings (head and neck cancer, colorectal cancer, pancreatic cancer, glioblastoma, hematological malignancy, breast cancer, non small cell lung cancer). All data have been published in multiple internationally peer-reviewed publications.

Boston, Massachusetts, United States

Alphageneron Pharmaceuticals Inc., USA and multimmune GmbH, Germany signed an Exclusive Worldwide License, and an Option to Purchase Agreement for its immunotherapy and diagnostics platform technology, in 2020.Alphageneron Pharmaceuticals Inc. is developing targeted autologous and allogeneic natural killer cell (‘NK cell’) cancer therapeutics for a number of indications, all of which are supported by a Companion Diagnostic. The Company’s lead clinical autologous therapy, AP-144™, is a 2nd generation autologous NK cell therapy originally developed by multimmune GmbH (ENKASTIM™) which involves the ex vivo activation of NK cells that have been expanded from the peripheral blood of patients to recognize and target tumors expressing a membrane form of heat shock protein 70 (Hsp70) by incubation with an Hsp70-derived peptide (‘TKD’) and low dose IL-2. Membrane Hsp70 is highly expressed by a wide range of cancers, but not by normal cells. The membrane Hsp70 expression status of a patient’s tumor is detected by measuring serum/plasma levels of circulating exosomal Hsp70 using a Companion Diagnostic ELISA.

Edinburgh, Scotland, United Kingdom

Cytomos is a dynamic early-stage company developing ground-breaking cell analysis systems that can be used alone or alongside conventional technologies such as flow cytometry. Cytomos Dielectric Spectroscopy (CDS) leverages cost-efficient microchip technology, providing streamlined testing strategies and economically viable cell therapies. The technology closely monitors a broad range of individual cell features simultaneously and collects data on intrinsic cellular properties in real-time, delivering unbiased, consistent, accurate and reliable predictive analytics for biomanufacturing and other applications.

Nottingham, England, United Kingdom

Nottingham, England, United Kingdom

Nottingham, United Kingdom

The John van Geest Cancer Research Centre was established in 2008, as a new research centre within the School of Science and Technology, as a direct result of core funding from the John and Lucille van Geest Foundation. This funding provided a £5m purpose-built Research Centre and a grant support for a team of more than 35 scientists, technicians and graduate students.Research focuses on the discovery and application of new cancer biomarkers for detecting cancer, monitoring disease progression, predicting therapeutic responses and developing new immunotherapeutic approaches. Progress in these areas is based on a fundamental understanding of cancer cell biology and immunobiology. The Centre is well equipped for the challenge of modern day cancer research, incorporating state-of-the-art flow cytometry and cell sorting instruments and technologies for discovering the genetic basis of the disease and developing new methods of diagnosis and treatment.

Nottingham, United Kingdom

Sheffield, England, United Kingdom

Scientific, Biomedical and Pharma Consultancy

Sheffield, United Kingdom

Chromocyte is now a part of Biocompare, the life science's industry’s leading product resource. The Chromocyte mission continues to focus on the Flow Cytometry community with beginners guides, reagents, instruments and training courses.

Sheffield, United Kingdom

Sheffield, United Kingdom

Sheffield, United Kingdom

London, England, United Kingdom

Detroit, Michigan, United States

Sheffield, England, United Kingdom

Phd, Immunology (Reproductive)

Title of PhD Thesis: An investigation into the immunoregulatory activities of human placental protein 14 (PP14)

Bsc (Hons), Biochemistry

Education record